Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5b5454abd09f216530c44daae0e81afa http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a36c66685971b78daf233b5999ead4c2 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate |
2019-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74ac54cf547acd3ff458cd53fa0cd176 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb23ae941f459d14fccf239a62aa3ece http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df1c5cc2dfdf9e9d09a523950047c87c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4e41d8ab4ac21f9c9b8ddb3297850c94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b4131a30bb85e643761423cb47a6ad93 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e36578bab19e0c8f75c6f783b0d89f2 |
publicationDate |
2020-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-20200108306-A |
titleOfInvention |
PD-L1 antibody or antigen-binding fragment thereof, and pharmaceutical use thereof |
abstract |
The present invention relates to novel PD-L1 antibodies and antigen-binding fragments thereof, and pharmaceutical uses thereof. The present invention relates to a humanized antibody comprising the CDRs of a PD-L1 antibody, a pharmaceutical composition comprising a PD-L1 antibody and an antigen-binding fragment thereof, and to the use of the PD-L1 antibody as a drug. The present invention relates to the use of a humanized PD-L1 antibody in the manufacture of a drug for the treatment of a disease or disorder associated with PD-L1. |
priorityDate |
2018-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |